Drug intelligence / Profile preview

acetaminophen + chlorpheniramine

Development stage
Unknown
Lead developer
Sichuan Defeit Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Acetaminophen + chlorpheniramine is a small molecule combination drug developed by Sichuan Defeit Pharmaceutical for the symptomatic relief of cold and allergy symptoms in children. Marketed as Children's Acetaminophen/Chlorphenamine Granules (小儿氨酚黄那敏颗粒), the product is administered orally in granule form. It contains two active ingredients: acetaminophen (paracetamol), an analgesic and antipyretic that reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system, and chlorpheniramine (chlorphenamine), an antihistamine that blocks histamine H1 receptors to relieve symptoms such as sneezing, runny nose, and itching. The product is approved and available in China for pediatric use.

Brand names
Children's Acetaminophen/Chlorphenamine Granules小儿氨酚黄那敏颗粒
Other names
paracetamol + chlorphenamineparacetamol + chlorpheniramineacetaminophen + chlorphenamine
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)mAChR (Muscarinic acetylcholine receptors)PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on acetaminophen + chlorpheniramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetaminophen + chlorpheniramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call